



Scientific Program

Thursday, January 31st, 2008

09:00-11:00

Session I: Non-alcoholic steatohepatitis

(NASH): from basic science to clinical applications

Chairpersons:

Ali Monis, Samir Kabil, Termchai Chainuvati

09:00 Cellular and molecular basis of fibrogenesis in NASH
Fabio Marra, Florence, Italy

09:24 Clinical aspects of NASH
Francesco Negro, Switzerland

09:48 Insulin resistance and fibrosis
Jacob George, Australia

10:12 Pathology of NASH and fibrosis
Puja Sakhuja, India

10:36 Steatosis, fibrosis and hepatitis C
Daniel Dhumeaux, France

11:00-11:30 **Coffee Break**

11:30-01:30

Session II: Antifibrotic drugs and biotechnological strategies

Chairpersons:

Serag Zakaria, Shoukry Hunter, Waseem Jafry

11:30 Molecular basis and clinical endpoints for the development of antifibrogenic drugs
Massimo Pinzani, Italy



- 12:00 Antifibrotic agents emerging from traditional herbal medicine
Norifumi Kawada, Osaka, Japan
- 12:30 Targeting fibrosis with antibodies
Matthew Wright, UK
- 01:00 Targeting fibrosis with selective drug carriers
Klaas Poelstra, Groningen, Netherlands

02:15-03:45 Luncheon Symposium

04:00-06:00

Session III: HBV treatment, reduction of fibrosis as an endpoint

Chairpersons:

Abdel-Fattah El-Fekky, Hussien Abdel-Hamid, Nurdan Tozun

- 04:00 Mechanisms of parenchymal damage in chronic HBV infection
Antonio Bertoletti, Singapore
- 04:30 Factors influencing liver disease progression in chronic hepatitis B
Josè Sollano, Philippines
- 05:00 New developments in the treatment of chronic hepatitis B
Stephanos Hadziyannis, Greece
- 05:30 End points in hepatitis B treatment
Nancy Leung, Hong Kong

07:30-09:30 Satellite Symposium